{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:10:56Z","timestamp":1791925856094,"version":"4.3.4"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013541","name":"European Calcified Tissue Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bone.2025.117769","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:22:28Z","timestamp":1766535748000},"page":"117769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Repurposing osteoporosis medications for other diseases: a narrative review by the European Calcified Tissue Society (ECTS)"],"prefix":"10.1016","volume":"204","author":[{"given":"Polyzois","family":"Makras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Yavropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha M.","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda Mihaela","family":"Naciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Paccou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Rolvien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem F.","family":"Lems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2025.117769_bb0005","series-title":"EU Innovation Offices, Proposal for a framework to support not-for-profit organisations and academia (institutions and individuals) in drug repurposing Available from: https:\/\/ec.europa.eu\/health\/system\/files\/2021-10\/pharm773_repurposing_annex_en_0.pdf","author":"Member States","year":"2019"},{"issue":"1","key":"10.1016\/j.bone.2025.117769_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1193-3","article-title":"The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC data mining and repurposing task force","volume":"14","author":"Southall","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"9902","key":"10.1016\/j.bone.2025.117769_bb0015","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2025.117769_bb0025","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.bone.2025.117769_bb0030","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.bone.2025.117769_bb0035","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"Storm","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"9041","key":"10.1016\/j.bone.2025.117769_bb0040","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0045","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study","volume":"90","author":"Reginster","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"19","key":"10.1016\/j.bone.2025.117769_bb0050","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.bone.2025.117769_bb0060","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","article-title":"Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension","volume":"17","author":"Brumsen","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2025.117769_bb0065","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s00198-003-1397-0","article-title":"Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis","volume":"14","author":"Morabito","year":"2003","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0070","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S8756-3282(03)00084-X","article-title":"Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis","volume":"33","author":"Braga","year":"2003","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00223-008-9179-5","article-title":"Intramuscular neridronate in postmenopausal women with low bone mineral density","volume":"83","author":"Adami","year":"2008","journal-title":"Calcif. Tissue Int."},{"issue":"8","key":"10.1016\/j.bone.2025.117769_bb0080","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1210\/jc.2010-2855","article-title":"The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density","volume":"96","author":"Fitzpatrick","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117769_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2016.11.012","article-title":"Prevalence and severity of arterial calcifications in pseudoxanthoma elasticum (PXE) compared to hospital controls. Novel insights into the vascular phenotype of PXE","volume":"256","author":"Kranenburg","year":"2017","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.bone.2025.117769_bb0090","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/ajmg.a.33329","article-title":"Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings","volume":"152A","author":"Plomp","year":"2010","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bone.2025.117769_bb0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2016.12.053","article-title":"Cerebral disease in a nationwide Dutch pseudoxanthoma elasticum cohort with a systematic review of the literature","volume":"373","author":"Kauw","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.bone.2025.117769_bb0100","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jcmg.2024.04.005","article-title":"The natural course of arterial calcifications in pseudoxanthoma Elasticum: a prospective cohort study","volume":"17","author":"van den Beukel","year":"2024","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096003","article-title":"The contribution of arterial calcification to peripheral arterial disease in pseudoxanthoma elasticum","volume":"9","author":"Leftheriotis","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/76102","article-title":"Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum","volume":"25","author":"Le Saux","year":"2000","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.bone.2025.117769_bb0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/jmg.2007.051094","article-title":"Mutation detection in the ABCC6 gene and genotype-phenotype analysis in a large international case series affected by pseudoxanthoma elasticum","volume":"44","author":"Pfendner","year":"2007","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12031047","article-title":"Plasma level of pyrophosphate is low in pseudoxanthoma elasticum owing to mutations in the ABCC6 gene, but it does not correlate with ABCC6 genotype","volume":"12","author":"Kozak","year":"2023","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.bone.2025.117769_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126502","article-title":"A plasma pyrophosphate cutoff value for diagnosing pseudoxanthoma Elasticum","volume":"25","author":"Rubera","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bone.2025.117769_bb0130","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/195911a0","article-title":"Mechanism of calcification: inhibitory role of pyrophosphate","volume":"195","author":"Fleisch","year":"1962","journal-title":"Nature"},{"issue":"56","key":"10.1016\/j.bone.2025.117769_bb0135","doi-asserted-by":"crossref","first-page":"30721","DOI":"10.18632\/oncotarget.10738","article-title":"Etidronate prevents, but does not reverse, ectopic mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(\u2212\/\u2212))","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bone.2025.117769_bb0140","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1080\/15384101.2015.1007809","article-title":"The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene","volume":"14","author":"Li","year":"2015","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.bone.2025.117769_bb0145","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2017.12.062","article-title":"Etidronate for prevention of ectopic mineralization in patients with pseudoxanthoma elasticum","volume":"71","author":"Kranenburg","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bone.2025.117769_bb0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.atherosclerosis.2019.10.004","article-title":"Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum","volume":"292","author":"Bartstra","year":"2020","journal-title":"Atherosclerosis"},{"issue":"16","key":"10.1016\/j.bone.2025.117769_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13164612","article-title":"Cyclical Etidronate reduces the progression of arterial calcifications in patients with pseudoxanthoma elasticum: a 6-year prospective observational study","volume":"13","author":"Harmsen","year":"2024","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051393","article-title":"Skin and arterial wall deposits of 18F-NaF and severity of disease in patients with pseudoxanthoma elasticum","volume":"9","author":"Gutierrez-Cardo","year":"2020","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.bone.2025.117769_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10122710","article-title":"Phenotypic features and genetic findings in a cohort of Italian pseudoxanthoma Elasticum patients and update of the ophthalmologic evaluation score","volume":"10","author":"Boraldi","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bone.2025.117769_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.119051","article-title":"Arterial calcification volume is associated with a higher risk of cardiovascular events in pseudoxanthoma elasticum","volume":"400","author":"Harmsen","year":"2025","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0175","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s00223-018-0495-0","article-title":"Chronic non-bacterial osteomyelitis: a review","volume":"104","author":"Buch","year":"2019","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0180","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/rheumatology\/keac443","article-title":"Clinical and therapeutic diversity in adult chronic nonbacterial osteomyelitis (CNO) of the sternocostoclavicular region: a meta-analysis","volume":"62","author":"Leerling","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard-2024-226446","article-title":"Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults","volume":"84","author":"Winter","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0190","first-page":"2016","article-title":"Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study","volume":"21","author":"Eggelmeijer","year":"1994","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.bone.2025.117769_bb0195","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/rheumatology\/41.10.1196","article-title":"Treatment of SAPHO with pamidronate","volume":"41","author":"Courtney","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0200","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/rheumatology\/keh149","article-title":"SAPHO syndrome treated with pamidronate: an open-label study of 10 patients","volume":"43","author":"Amital","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0205","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kei160","article-title":"The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome","volume":"45","author":"Solau-Gervais","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.bone.2025.117769_bb0210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2008.10.046","article-title":"Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate","volume":"61","author":"Galadari","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.bone.2025.117769_bb0215","first-page":"112","article-title":"Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature","volume":"27","author":"Colina","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.bone.2025.117769_bb0220","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00296-009-1021-5","article-title":"SAPHO syndrome in an adult with ulcerative colitis responsive to intravenous pamidronate: a case report and review of the literature","volume":"30","author":"Siau","year":"2010","journal-title":"Rheumatol. Int."},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0225","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jbspin.2014.01.017","article-title":"SAPHO syndrome treatment with intravenous pamidronate. Retrospective study of 22 patients","volume":"81","author":"Delattre","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0230","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3899\/jrheum.140342","article-title":"The SAPHO syndrome: a single-center study of 41 adult patients","volume":"42","author":"Aljuhani","year":"2015","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.bone.2025.117769_bb0235","first-page":"663","article-title":"Efficacy of bisphosphonates in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a prospective open study","volume":"37","author":"Li","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.bone.2025.117769_bb0240","first-page":"1263","article-title":"A single cohort, open-label study of the efficacy of pamidronate for palmoplantar pustulosis in synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome","volume":"38","author":"Wu","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bone.2025.117769_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.621604","article-title":"Sternocostoclavicular hyperostosis: positive clinical and radiological response on pamidronate","volume":"12","author":"Leerling","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.bone.2025.117769_bb0250","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/03009742.2020.1724324","article-title":"Pamidronate in chronic non-bacterial osteomyelitis: a randomized, double-blinded, placebo-controlled pilot trial","volume":"49","author":"Andreasen","year":"2020","journal-title":"Scand. J. Rheumatol."},{"issue":"7","key":"10.1016\/j.bone.2025.117769_bb0255","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"10.1016\/j.bone.2025.117769_bb0260","doi-asserted-by":"crossref","first-page":"ziae114","DOI":"10.1093\/jbmrpl\/ziae114","article-title":"Pamidronate for pain in adult chronic nonbacterial osteitis: protocol of a randomized, double-blind, placebo-controlled trial","volume":"8","author":"Leerling","year":"2024","journal-title":"JBMR Plus"},{"issue":"4","key":"10.1016\/j.bone.2025.117769_bb0265","first-page":"7","article-title":"Complex regional pain syndrome (CRPS) in orthopaedics: an overview","volume":"33","author":"Cowell","year":"2019","journal-title":"Orthop. Traumatol."},{"issue":"9","key":"10.1016\/j.bone.2025.117769_bb0270","article-title":"The analgesic efficacy of therapies used for complex regional pain syndrome: a systematic review","volume":"17","author":"Shekarsarai","year":"2025","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.bone.2025.117769_bb0275","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/rheumatology\/keac060","article-title":"Pharmacological treatment in adult patients with CRPS-I: a systematic review and meta-analysis of randomized controlled trials","volume":"61","author":"Fassio","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2025.117769_bb0280","article-title":"Treatment of complex regional pain syndrome type I with bisphosphonates","volume":"1","author":"Giusti","year":"2015","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0285","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/rheumatology\/kes312","article-title":"Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study","volume":"52","author":"Varenna","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2025.117769_bb0290","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211014020","article-title":"Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Varenna","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.bone.2025.117769_bb0295","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221142274","article-title":"Long-term efficacy and safety of neridronate treatment in patients with complex regional pain syndrome type 1: a pre-specified, open-label, extension study","volume":"14","author":"Varenna","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.bone.2025.117769_bb0300","doi-asserted-by":"crossref","DOI":"10.1177\/11795441241294098","article-title":"Is CRPS-1 a chronic disabling disease? A long-term, real-life study on patients treated with neridronate","volume":"17","author":"Varenna","year":"2024","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"issue":"9","key":"10.1016\/j.bone.2025.117769_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28422","article-title":"The annual incidence of Langerhans cell histiocytosis among adults living in Greece","volume":"67","author":"Makras","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bone.2025.117769_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107032","article-title":"Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis","volume":"126","author":"Goyal","year":"2023","journal-title":"Leuk. Res."},{"issue":"22","key":"10.1016\/j.bone.2025.117769_bb0315","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bone.2025.117769_bb0320","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bone.2025.117769_bb0325","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1210\/clinem\/dgae827","article-title":"Approach to the patient: from endocrinopathy to the diagnosis of a histiocytic disorder","volume":"110","author":"Makras","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0330","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1210\/jc.2014-2654","article-title":"Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis","volume":"100","author":"Makras","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2025.117769_bb0335","doi-asserted-by":"crossref","first-page":"E618","DOI":"10.1210\/jc.2011-2962","article-title":"Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis","volume":"97","author":"Makras","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117769_bb0340","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.metabol.2017.01.004","article-title":"Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis","volume":"69","author":"Makras","year":"2017","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.bone.2025.117769_bb0345","doi-asserted-by":"crossref","first-page":"E168","DOI":"10.1002\/ajh.26936","article-title":"Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: a prospective clinical trial","volume":"98","author":"Makras","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.bone.2025.117769_bb0350","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00198-025-07538-6","article-title":"No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial","volume":"36","author":"Makras","year":"2025","journal-title":"Osteoporos. Int."},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0355","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/art.22160","volume":"54","author":"Bingham","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.bone.2025.117769_bb0360","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2011-200970","article-title":"Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial","volume":"71","author":"Laslett","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.bone.2025.117769_bb0365","article-title":"Incidence of total knee arthroplasty in older females with knee osteoarthritis and osteoporosis treated with denosumab compared with those treated using bisphosphonates: a population-based cohort study","volume":"14","author":"Yu","year":"2024","journal-title":"Life (Basel)"},{"issue":"9","key":"10.1016\/j.bone.2025.117769_bb0370","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1136\/annrheumdis-2017-212364","article-title":"Bisphosphonates: a therapeutic option for knee osteoarthritis?","volume":"77","author":"Lems","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0375","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41591-024-02822-0","article-title":"RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial","volume":"30","author":"Wittoek","year":"2024","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0380","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0385","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/mr\/roae002","article-title":"Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: a post hoc analysis of a multicentre, open-label, randomised, parallel-group study","volume":"34","author":"Iwamoto","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.bone.2025.117769_bb0390","article-title":"The efficacy of Denosumab in patients with rheumatoid arthritis: a systematic review and pooled analysis of randomized or matched data","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0395","doi-asserted-by":"crossref","first-page":"rkab099","DOI":"10.1093\/rap\/rkab099","article-title":"Therapeutic efficacy of denosumab for rheumatoid arthritis: a systematic review and meta-analysis","volume":"5","author":"Yagita","year":"2021","journal-title":"Rheumatol. Adv. Pract."},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0400","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3899\/jrheum.201376","article-title":"Effects of Denosumab in Japanese patients with rheumatoid arthritis treated with conventional Antirheumatic drugs: 36-month extension of a phase III study","volume":"48","author":"Tanaka","year":"2021","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.bone.2025.117769_bb0405","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0410","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1080\/14712598.2016.1238455","article-title":"Natpara for the treatment of hypoparathyroidism","volume":"16","author":"Marcucci","year":"2016","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.bone.2025.117769_bb0415","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0420","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1210\/jc.2017-01471","article-title":"Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic Hypoparathyroidism","volume":"103","author":"Vokes","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2025.117769_bb0425","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12020-020-02577-x","article-title":"Chronic hypoparathyroidism and treatment with teriparatide","volume":"72","author":"Marcucci","year":"2021","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.bone.2025.117769_bb0430","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0435","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J. Pediatr."},{"issue":"7","key":"10.1016\/j.bone.2025.117769_bb0440","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jbmr.4566","article-title":"Safety and efficacy of PTH 1-34 and 1-84 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials","volume":"37","author":"Puliani","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0445","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1210\/jc.2016-2530","article-title":"PTH(1-34) for the primary prevention of postthyroidectomy hypocalcemia: the THYPOS trial","volume":"101","author":"Palermo","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.bone.2025.117769_bb0450","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/jc.2015-1855","article-title":"PTH(1-34) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life","volume":"100","author":"Santonati","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bone.2025.117769_bb0455","doi-asserted-by":"crossref","first-page":"R229","DOI":"10.1530\/EC-20-0366","article-title":"Challenges in the management of chronic hypoparathyroidism","volume":"9","author":"Zavatta","year":"2020","journal-title":"Endocr. Connect."},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0460","doi-asserted-by":"crossref","first-page":"E2207","DOI":"10.1210\/jc.2013-4009","article-title":"A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis","volume":"99","author":"Halse","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117769_bb0465","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2014.04.015","article-title":"AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women","volume":"64","author":"John","year":"2014","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0470","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/jbmr.2551","article-title":"Calcilytic ameliorates abnormalities of mutant Calcium-Sensing Receptor (CaSR) Knock-in mice mimicking Autosomal Dominant Hypocalcemia (ADH)","volume":"30","author":"Dong","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2025.117769_bb0475","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa145","article-title":"A New Therapeutic Approach Using a Calcilytic (AXT914) for postsurgical hypoparathyroidism in female rats","volume":"161","author":"Lim","year":"2020","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.bone.2025.117769_bb0480","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/jbmr.3747","article-title":"Treatment of autosomal dominant hypocalcemia type 1 with the Calcilytic NPSP795 (SHP635)","volume":"34","author":"Roberts","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"13","key":"10.1016\/j.bone.2025.117769_bb0485","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1056\/NEJMc2302708","article-title":"Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1","volume":"389","author":"Gafni","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0490","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3803\/EnM.2024.2035","article-title":"Potential of calcilytics as a novel treatment for post-surgical hypoparathyroidism","volume":"39","author":"Choi","year":"2024","journal-title":"Endocrinol Metab. (Seoul)"},{"issue":"10182","key":"10.1016\/j.bone.2025.117769_bb0495","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","article-title":"Osteoarthritis","volume":"393","author":"Hunter","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bone.2025.117769_bb0500","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/art.20124","article-title":"The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model","volume":"50","author":"Hayami","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0505","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00223-013-9812-9","article-title":"Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid","volume":"94","author":"Devogelaer","year":"2014","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0510","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/joca.2001.0506","article-title":"The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage","volume":"10","author":"Muehleman","year":"2002","journal-title":"Osteoarthr. Cartil."},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0515","first-page":"4901","article-title":"Protective effect of zoledronic acid on articular cartilage and subchondral bone of rabbits with experimental knee osteoarthritis","volume":"14","author":"She","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0520","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/annrheumdis-2012-202989","article-title":"Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative","volume":"73","author":"Laslett","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0525","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2106\/JBJS.16.00385","article-title":"Bisphosphonate use and the risk of undergoing total knee arthroplasty in osteoporotic patients with osteoarthritis: a nationwide cohort study in Taiwan","volume":"99","author":"Fu","year":"2017","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.bone.2025.117769_bb0530","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19880054","article-title":"Zoledronic acid plus methylprednisolone versus zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial","volume":"11","author":"Cai","year":"2019","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"15","key":"10.1016\/j.bone.2025.117769_bb0535","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2020.2938","article-title":"Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with Bone marrow lesions: a Randomized Clinical Trial","volume":"323","author":"Cai","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.bone.2025.117769_bb0540","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/art.42831","volume":"76","author":"Cai","year":"2024","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.bone.2025.117769_bb0545","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/rheumatology\/keab786","article-title":"Intravenous bisphosphonates do not improve knee pain or bone marrow lesions in people with knee osteoarthritis: a meta-analysis","volume":"61","author":"Zhang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0550","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1359\/jbmr.2001.16.2.299","article-title":"Strontium ranelate increases cartilage matrix formation","volume":"16","author":"Henrotin","year":"2001","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0555","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bone.2011.06.005","article-title":"Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts","volume":"49","author":"Tat","year":"2011","journal-title":"Bone"},{"issue":"2 Suppl 1","key":"10.1016\/j.bone.2025.117769_bb0560","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.bone.2005.07.029","article-title":"Strontium ranelate: a physiological approach for optimizing bone formation and resorption","volume":"38","author":"Marie","year":"2006","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0565","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3892\/etm.2022.11131","article-title":"The anti-inflammation effect of strontium ranelate on rat chondrocytes with or without IL-1beta in vitro","volume":"23","author":"Yu","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bone.2025.117769_bb0570","article-title":"Strontium ranelate retards disc degradation and improves endplate and bone micro-architecture in ovariectomized rats with lumbar fusion induced - adjacent segment disc degeneration","volume":"20","author":"Sun","year":"2024","journal-title":"Bone Rep."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0575","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/aps.2012.167","article-title":"Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model","volume":"34","author":"Yu","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"issue":"13","key":"10.1016\/j.bone.2025.117769_bb0580","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.7150\/ijms.86665","article-title":"Strontium Ranelate ameliorates intervertebral disc degeneration via regulating TGF-beta1\/NF-kappaB axis","volume":"20","author":"Sun","year":"2023","journal-title":"Int. J. Med. Sci."},{"issue":"10","key":"10.1016\/j.bone.2025.117769_bb0585","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00011-015-0860-7","article-title":"Strontium ranelate analgesia in arthritis models is associated to decreased cytokine release and opioid-dependent mechanisms","volume":"64","author":"de Melo Nunes","year":"2015","journal-title":"Inflamm. Res."},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0590","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2025.117769_bb0595","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard.2007.075572","article-title":"Effects of strontium ranelate on spinal osteoarthritis progression","volume":"67","author":"Bruyere","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0600","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2012-202231","article-title":"Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial","volume":"72","author":"Reginster","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0605","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2013-203989","article-title":"Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss","volume":"74","author":"Pelletier","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"24","key":"10.1016\/j.bone.2025.117769_bb0610","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1001\/jama.2018.19319","article-title":"Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis","volume":"320","author":"Gregori","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2025.117769_bb0615","article-title":"Cessation of strontium ranelate supply","volume":"357","author":"Bolland","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2025.117769_bb0620","article-title":"Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency","volume":"354","author":"Bolland","year":"2016","journal-title":"BMJ"},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2025.117769_bb0625","doi-asserted-by":"crossref","first-page":"P99","DOI":"10.1359\/jbmr.06s219","article-title":"Spectrum and natural history of fibrous dysplasia of bone","volume":"21","author":"Collins","year":"2006","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2025.117769_bb0630","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J","article-title":"The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks","volume":"187","author":"Riminucci","year":"1999","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.bone.2025.117769_bb0635","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","article-title":"Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment","volume":"35","author":"Chapurlat","year":"2004","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bone.2025.117769_bb0640","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1210\/jc.2003-030050","article-title":"Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone","volume":"88","author":"Plotkin","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2025.117769_bb0645","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0650","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2025.117769_bb0655","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMc2214862","article-title":"Safety and efficacy of denosumab for fibrous dysplasia of bone","volume":"388","author":"de Castro","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bone.2025.117769_bb0660","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1210\/clinem\/dgae867","article-title":"Safety and efficacy of moderate-dose Denosumab in fibrous dysplasia: observational results from a phase 2 clinical trial","volume":"110","author":"Szymczuk","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117769_bb0665","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jcb.240590808","article-title":"Alternate antiestrogens and approaches to the prevention of breast cancer","volume":"22","author":"Jordan","year":"1995","journal-title":"J. Cell. Biochem. Suppl."},{"issue":"1","key":"10.1016\/j.bone.2025.117769_bb0670","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1038\/s41598-025-89915-z","article-title":"Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis","volume":"15","author":"Alwashmi","year":"2025","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.bone.2025.117769_bb0675","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3949\/ccjm.72.11.1033","article-title":"What is a \u2018failure\u2019 of bisphosphonate therapy for osteoporosis?","volume":"72","author":"Carey","year":"2005","journal-title":"Cleve. Clin. J. Med."},{"issue":"7","key":"10.1016\/j.bone.2025.117769_bb0680","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/aid.2020.0095","article-title":"Fake science: XMRV, COVID-19, and the toxic legacy of Dr. Judy Mikovits","volume":"36","author":"Neil","year":"2020","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"5","key":"10.1016\/j.bone.2025.117769_bb0685","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.healthpol.2021.03.013","article-title":"COVID-19 vaccine challenges: what have we learned so far and what remains to be done?","volume":"125","author":"Forman","year":"2021","journal-title":"Health Pol."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225003813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225003813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:26:37Z","timestamp":1786033597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225003813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":137,"alternative-id":["S8756328225003813"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117769","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing osteoporosis medications for other diseases: a narrative review by the European Calcified Tissue Society (ECTS)","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117769"}}